Idera Pharmaceuticals Inc  

(Public, NASDAQ:IDRA)   Watch this stock  
Find more results for IDRA
3.84
May 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.93 - 5.48
Open     -
Vol / Avg. 0.00/1.82M
Mkt cap 452.64M
P/E     -
Div/yield     -
EPS -0.47
Shares 117.88M
Beta 2.64
Inst. own 48%
Aug 10, 2015
Q2 2015 Idera Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Jun 24, 2015
Idera Pharmaceuticals, Inc. at JMP Securities 2015 Life Sciences Conference - 12:30PM EDT - Add to calendar
Jun 1, 2015
Idera Pharmaceuticals, Inc. at Jefferies 2015 Global Healthcare Conference - 1:30PM EDT - Add to calendar
May 11, 2015
Q1 2015 Idera Pharmaceuticals Inc Earnings Release
Apr 14, 2015
Idera Pharmaceuticals Inc at Needham Healthcare Conference - Webcast
Mar 12, 2015
Q4 2014 Idera Pharmaceuticals Inc Earnings Release
Mar 2, 2015
Idera Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -36708.82% -52934.25%
Operating margin -36832.35% -53084.93%
EBITD margin - -52810.96%
Return on average assets -58.30% -87.53%
Return on average equity -63.91% -120.75%
Employees 45 -
CDP Score - -

Address

167 Sidney St
CAMBRIDGE, MA 02139-4237
United States - Map
+1-617-6795500 (Phone)
+1-617-6795592 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates. The Company is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors (TLRs). It is also evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA. During the year ended December 31, 2011, the Company collaborated with Merck Sharp & Dohme Corp., for the use of agonists of TLRs 7, 8, and 9 as vaccine adjuvants for cancer, infectious diseases, and Alzheimer’s disease. In November 2011, the Company reacquired rights to IMO-2055 from Merck KGaA, Darmstadt, Germany, its former collaborator.

Officers and directors

James A. Geraghty Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Vincent J. Milano President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Youssef El Zein Independent Vice Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Louis J. Arcudi III Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary
Age: 54
Bio & Compensation  - Reuters
Robert Clayton Fletcher Senior Vice President - Business Development and Strategic Planning
Age: 52
Bio & Compensation  - Reuters
Robert A. Doody Jr. Vice President - Investor Relations and Corporate Communications
Bio & Compensation  - Reuters
William S. Reardon CPA Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Sudhir Agrawal D. Phil. Director, President of Research
Age: 61
Bio & Compensation  - Reuters
Julian C. Baker Independent Director
Age: 49
Bio & Compensation  - Reuters
Mark A. Goldberg M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters